Matrix has filed an abbreviated new drug application with the FDA seeking to market a generic version of Azor. Daiichi Sankyo and Daiichi Sankyo, Inc intend to vigorously defend the patent, which expires in April 2016 in the US.
Olmesartan medoxomil is an angiotensin II receptor antagonist that Daiichi Sankyo independently developed, and is marketed in over 50 countries as an antihypertensive drug which suppresses vasoconstriction by affecting the rennin-angiotensin system to control blood pressure.